



**Geistlich**  
Pharma

**Geistlich TauroSept®**  
What your catheter needs.



Strong protection.  
Thorough treatment.

# Characteristics



## ► Prevention of catheter-related blood stream infections (CRBSI)

- › Broad bactericidal and fungicidal spectrum<sup>1</sup>
- › Effective against antibiotic-resistant bacteria<sup>2</sup>
- › No development of bacterial resistance known<sup>3</sup>

## ► Treatment of colonized catheters

- › Resolves the catheter biofilm<sup>4,5</sup>
- › Detoxifies endo- and exotoxins<sup>6</sup>

## ► Prevention of catheter occlusion

- › Inhibition of staphylocoagulase activity<sup>7</sup>
- › Evidence for inhibition of blood coagulation factors and prevention of surface activation of platelets<sup>8,9</sup>

## ► Very good tolerance

- › No heparin, no citrate<sup>17</sup>
- › Can be flushed in adults<sup>10</sup>
- › Rapidly metabolized to Taurine, H<sub>2</sub>O and CO<sub>2</sub><sup>11</sup>

# Benefits

-84%

**Catheter-related blood stream infections (CRBSI)<sup>12-16\*</sup>**

+80%

**Successful treatment of catheter infections<sup>4,5</sup>**

-71%

**Catheter occlusions<sup>12\*\*</sup>**

-51%

**Overall treatment costs<sup>15,16\*\*\*</sup>**

\*Compared to 100/150 U/ml Heparin and Saline | \*\*Compared to 150 U/ml Heparin  
\*\*\*Compared to 0.9 % Saline



## ► TauroSept® can be used with any vascular access device

Follow the manufacturer's instructions for the particular catheter utilized. Specific catheter volumes are associated with each device and must be strictly followed. Use of the device by patients requires proper training by authorized health care personnel. If legally required, the training must be documented.<sup>17</sup>




# Clinical Studies

## Prevention of CRBSI



## Treatment of Colonized Catheters



# Guidelines

## European Renal Best Practice (ERBP)

“The preventive use of antimicrobial locks is advocated to reduce the rate of CRBSI.”<sup>18</sup>

## ESPEN guideline on home parenteral nutrition

“As an additional strategy to prevent CRBSIs, taurolidine locking should be used because of its favorable safety and cost profile.”<sup>19</sup>

## GAVeCeLT consensus

“...the drugs most likely to be used as antibacterial lock are taurolidine and citrate, which have optimal characteristics in terms of safety, efficacy and cost effectiveness.”<sup>20</sup>

---

### References

- 1 Torres-Viera C et al. *Antimicrob. Agents Chemother.* 2000. 44 (6):1720–1724.
- 2 Traub WH et al. *Chemotherapy.* 1993. 39 (5):322–30.
- 3 Olthof ED et al. *Clin Nutr.* 2013. 32 (4):538–42.
- 4 Koldehoff M and Zakrzewski JL. *Int J Antimicrob Agents.* 2004. 24 (5):491–5.
- 5 Weber M et al. *Zentralbl Chir.* 2009. 134 (4):350–6.
- 6 Blenkarn JI. *Surg. Res. Comm.* 1987. 2:149–155.
- 7 Reinmüller J et al. *Hämostaseologie* 1999. 19:94–7.
- 8 Kaptanoglu L et al. *Eur J of Physiol* 2008. 578:238–41.
- 9 Reinmüller J. *Zentralbl Chir.* 1999. 124 (Suppl 4):13–8.
- 10 Gong L et al. *J Clin Pharmacol* 2007. 47(6): 697–703.
- 11 Steinbach-Lebbin C et al. *Drug. Res.* 1982. 32(12):1542–1546.
- 12 Olthof ED et al. *PLoS One.* 2014. 9 (11):e111216.
- 13 Bisseling TM et al. *Clin Nutr.* 2010. 29 (4):464–8.
- 14 Jurewitsch B and Jeejeebhoy KN. *Clin Nutr.* 2005. 24 (3):462–5
- 15 Wouters Y et al. *AP & T.* 2018. 48 (4):410–422.
- 16 Arnoriaga Rodriguez M et al. 2018. *Nutr Hosp.* 35(4):761–766.
- 17 TauroSept® – Instructions for Use. 06/2015.
- 18 Vanholder R et al. *NDT Plus.* 2010. 3:234–246.
- 19 Pironi L et al. *Clin Nutr.* 2020. 39(6):1645–1666.
- 20 Pittiruti M et al. *J Vasc Access.* 2016. 17 (6):453–464.



More details about  
TauroSept®:  
[www.geistlich-medical.com](http://www.geistlich-medical.com)



**Manufacturer**  
Geistlich Pharma AG  
Bahnhofstrasse 40  
6110 Wolhusen, Switzerland  
Phone +41 41 492 55 55  
Fax +41 41 492 56 39  
[www.geistlich-medical.com](http://www.geistlich-medical.com)